Compare BY & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BY | CMPS |
|---|---|---|
| Founded | 1914 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2017 | 2020 |
| Metric | BY | CMPS |
|---|---|---|
| Price | $32.88 | $9.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $36.00 | $25.38 |
| AVG Volume (30 Days) | 211.6K | ★ 5.1M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ 5.09 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.89 | N/A |
| Revenue Next Year | $3.15 | N/A |
| P/E Ratio | $38.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.75 | $2.25 |
| 52 Week High | $34.33 | $10.21 |
| Indicator | BY | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 64.78 |
| Support Level | $31.94 | $5.95 |
| Resistance Level | $34.11 | $10.21 |
| Average True Range (ATR) | 0.75 | 0.81 |
| MACD | -0.15 | 0.11 |
| Stochastic Oscillator | 39.61 | 78.80 |
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through a wholly-owned subsidiary of Byline Bank.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.